FOLH1 and neoplasm: Thus, in clinical studies assessing the prognostic value of PSMA PET imaging in early-stage PCa [10–13, 15, 47], the most common metrics adopted to quantify the PSMA-targeting tracer accumulation at PET imaging (i.e., SUV) may be influenced by several variables beyond FOLH1 expression, including PSMA-expressing cellular density or tumour burden.